JP3253861B2 - Permselective hollow fiber membrane - Google Patents
Permselective hollow fiber membraneInfo
- Publication number
- JP3253861B2 JP3253861B2 JP24397296A JP24397296A JP3253861B2 JP 3253861 B2 JP3253861 B2 JP 3253861B2 JP 24397296 A JP24397296 A JP 24397296A JP 24397296 A JP24397296 A JP 24397296A JP 3253861 B2 JP3253861 B2 JP 3253861B2
- Authority
- JP
- Japan
- Prior art keywords
- hollow fiber
- fiber membrane
- coefficient
- membrane
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000012528 membrane Substances 0.000 title claims description 69
- 239000012510 hollow fiber Substances 0.000 title claims description 62
- 239000008280 blood Substances 0.000 claims description 23
- 210000004369 blood Anatomy 0.000 claims description 23
- 230000014759 maintenance of location Effects 0.000 claims description 21
- 238000007873 sieving Methods 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 238000000108 ultra-filtration Methods 0.000 claims description 17
- 230000035699 permeability Effects 0.000 claims description 15
- 229920002284 Cellulose triacetate Polymers 0.000 claims description 6
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 claims description 6
- 238000001631 haemodialysis Methods 0.000 claims description 5
- 230000000322 hemodialysis Effects 0.000 claims description 5
- 239000000126 substance Substances 0.000 description 17
- 238000001914 filtration Methods 0.000 description 16
- 239000002904 solvent Substances 0.000 description 14
- 238000009987 spinning Methods 0.000 description 13
- 239000011162 core material Substances 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 229920002678 cellulose Polymers 0.000 description 9
- 239000001913 cellulose Substances 0.000 description 9
- 238000002615 hemofiltration Methods 0.000 description 8
- 238000000502 dialysis Methods 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000005345 coagulation Methods 0.000 description 6
- 230000015271 coagulation Effects 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- 206010006002 Bone pain Diseases 0.000 description 3
- 206010064553 Dialysis amyloidosis Diseases 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 3
- 238000000635 electron micrograph Methods 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920001059 synthetic polymer Polymers 0.000 description 3
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 238000002166 wet spinning Methods 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229920001747 Cellulose diacetate Polymers 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- SMEGJBVQLJJKKX-HOTMZDKISA-N [(2R,3S,4S,5R,6R)-5-acetyloxy-3,4,6-trihydroxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)OC(=O)C)O)O SMEGJBVQLJJKKX-HOTMZDKISA-N 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- QKIUAMUSENSFQQ-UHFFFAOYSA-N dimethylazanide Chemical compound C[N-]C QKIUAMUSENSFQQ-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- External Artificial Organs (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Description
【0001】[0001]
【発明の属する技術分野】本発明は、血液浄化中空糸膜
に関する。例えば、腎不全患者用の人工透析膜、特に最
近透析患者の長期合併症との関係で注目されている分子
量10,000以上のβ2 ―マイクログロブリン(β2
―MGと称する)に代表される中高分子量物質の除去に
適している中空糸膜に関する。また単に血液透析濾過、
血液濾過にも適している中空糸膜に関する。TECHNICAL FIELD The present invention relates to a blood purification hollow fiber membrane. For example, artificial dialysis membranes for patients with renal failure, particularly β 2 -microglobulin (β 2) having a molecular weight of 10,000 or more, which has recently been attracting attention in relation to long-term complications of dialysis patients.
-MG), which is suitable for removing medium-high molecular weight substances. Also simply hemodiafiltration,
The present invention relates to a hollow fiber membrane that is also suitable for hemofiltration.
【0002】[0002]
【従来の技術】近年、透析患者の長期合併症と関連し
て、透析アミロイドシスの原因物質と考えられているβ
2 ―MG(分子量11,800)、掻痒感、高脂血症と
関係すると考えられる副甲状腺ホルモン(分子量約9,
500)、関節痛、骨痛に係わると考えられる分子量2
〜4万の物質、など比較的中高分子量領域の有害物質の
除去の必要性がさけばれている。一方、人体に必須のア
ルブミン(分子量66,000)の損失は極力避けなけ
ればならない。2. Description of the Related Art In recent years, in connection with long-term complications of dialysis patients, β which is considered to be a causative substance of dialysis amyloidosis
2- MG (molecular weight 11,800), parathyroid hormone (molecular weight of about 9,
500), molecular weight 2 thought to be related to joint pain and bone pain
The need to remove harmful substances in the relatively medium to high molecular weight region, such as ~ 40,000 substances, has been avoided. On the other hand, loss of albumin (molecular weight: 66,000), which is essential for the human body, must be avoided as much as possible.
【0003】すなわち、分子量4〜5万以下の物質の透
過性に優れ、一方分子量6万以上の物質の阻止性のよい
分画分子量のシャープカット性の良好な選択透過性膜が
望まれている。[0003] That is, there is a demand for a permselective membrane having excellent permeability for substances having a molecular weight of 40,000 or less and 50,000 or less, and having good rejection of substances having a molecular weight of 60,000 or more and having a good sharp cut of the molecular weight. .
【0004】しかるに、従来、ポリサルホンなどの合成
高分子では、例えば特公平2―18695号や特公平5
―54373号各公報に見られるように、比較的上記要
求を満たしたものが得られている。しかし、セルロース
誘導体、特にセルローストリアセテートでは、例えば特
に特公昭58―24165号公報に見られるように、中
空糸を湿式紡糸するときの芯剤として流動パラフィン、
高級アルコール、イソプロピルミリステートなど、トリ
アセテート紡糸原液に対して凝固性のないものを使用す
るため、紡糸時の曵糸性を高くするためには紡糸原液に
おけるトリアセテートの濃度を高めざるを得ず、また紡
糸原液の凝固は必然的にノズルから出糸後、中空糸外面
から凝固液で固化させることになるため、中空糸外面に
緻密構造層が形成される。However, conventionally, in the case of synthetic polymers such as polysulfone, for example, Japanese Patent Publication No.
As can be seen from the publications of JP-A-54373, those which relatively satisfy the above requirements have been obtained. However, in the case of cellulose derivatives, especially cellulose triacetate, for example, liquid paraffin, as a core agent for wet spinning a hollow fiber, as shown in JP-B-58-24165.
Higher alcohols, isopropyl myristate, etc., which do not have coagulability with the triacetate spinning dope, are used. The coagulation of the spinning solution is inevitably performed by the coagulation liquid from the outer surface of the hollow fiber after spinning from the nozzle, so that a dense structure layer is formed on the outer surface of the hollow fiber.
【0005】これらの理由により、従来セルロース誘導
体中空糸は、合成ポリマーの膜に比べて、緻密層と多孔
層の密度差が小さく、全体として均一層に近く、物質の
透過性能が十分とはいえなかった。[0005] For these reasons, the conventional cellulose derivative hollow fiber has a smaller density difference between the dense layer and the porous layer than the synthetic polymer membrane, is close to a uniform layer as a whole, and has a sufficient substance permeability. Did not.
【0006】一方特開平8―970号公報には、芯剤に
N2 ガスを使用することにより、トリアセテートであり
ながら透過性を向上させた中空糸膜が開示されている。On the other hand, JP-A-8-970 discloses a hollow fiber membrane which is triacetate and has improved permeability by using N 2 gas as a core agent.
【0007】これによると、純水の限外濾過係数10〜
200ml/m2 ・mmHg・Hrで、β2 ―MGの篩
係数0.2以上の中空糸膜であって、血液濾過開始後4
時間経過しても膜の血液透水性とβ2 ―MGの篩係数が
血液濾過開始時の値に比べて90%以上を示すことを特
徴とする血液透析膜が得られている。According to this, the ultrafiltration coefficient of pure water is 10
200 ml / m 2 · mmHg · Hr, a hollow fiber membrane having a β 2 -MG sieving coefficient of 0.2 or more,
A hemodialysis membrane is obtained, characterized in that the blood permeability of the membrane and the sieving coefficient of β 2 -MG show 90% or more of the values at the start of hemofiltration even after a lapse of time.
【0008】しかし、該公報に開示されている気体を芯
剤としたトリアセテートの紡糸法では、紡糸が難しいた
め低ポリマー濃度での紡糸が困難であり、水の限外濾過
係数は実施例に示されている如く、10〜120ml/
Hr・mmHg・m2 と比較的低く、高い限外濾過係数
の中空糸膜が得がたい。また、芯剤として気体を用いる
場合は、芯剤に凝固性がないため、内面緻密層の形成は
難しく、膜構造としては緻密層と、多孔層との密度差が
小さく、透過性の優れた合成ポリマーの様な2層構造の
膜が得られない。そのため血液透析での長期合併症で問
題になっているβ2 ―MGに代表される中高分子量物質
の除去を大幅に改善することが困難である。However, in the spinning method of triacetate using a gas as a core agent disclosed in the publication, spinning at a low polymer concentration is difficult because spinning is difficult, and the ultrafiltration coefficient of water is shown in Examples. 10 to 120 ml /
It is difficult to obtain a hollow fiber membrane having a relatively low Hr · mmHg · m 2 and a high ultrafiltration coefficient. When a gas is used as the core material, since the core material does not have coagulation properties, it is difficult to form an inner dense layer, and as a film structure, the density difference between the dense layer and the porous layer is small, and the permeability is excellent. A two-layer film like a synthetic polymer cannot be obtained. Therefore, it is difficult to significantly improve the removal of medium-high molecular weight substances represented by β 2 -MG, which is a problem due to long-term complications in hemodialysis.
【0009】この様に、膜構造の緻密層と多孔層の密度
差が不明確なために、透過性及び分画性においても改良
の余地がある。As described above, since the density difference between the dense layer and the porous layer of the membrane structure is unclear, there is still room for improvement in permeability and fractionability.
【0010】[0010]
【発明が解決しようとする課題】本発明の目的は、限外
濾過係数とβ2 ―MGの篩係数とが共に大きい値であ
る、セルロース誘導体からなる高性能の選択透過性中空
糸膜であり、かつ血液濾過透析における透水性保持率及
びβ2 ―MGの篩係数の保持率が高く、しかして濾過性
能の経時的劣化の少ない選択透過性中空糸膜を提供する
ことにある。An object of the present invention is to provide a high-performance permselective hollow fiber membrane comprising a cellulose derivative, wherein both the ultrafiltration coefficient and the β 2 -MG sieve coefficient are large. Another object of the present invention is to provide a selectively permeable hollow fiber membrane having high water permeability retention rate and high retention rate of β 2 -MG sieving coefficient in hemofiltration dialysis, and having little deterioration over time in filtration performance.
【0011】[0011]
【課題を解決するための手段】本発明者は、かかる目標
を達成するために鋭意研究した結果、内面に極薄の緻密
層を有し、支持層に多孔層を有する2層構造の中空糸膜
で、特定の水透過性能を有する場合に、血液処理時の透
水性保持率及びβ2 ―MGの篩係数の保持率の優れた低
劣化性のセルロース誘導体選択透過性中空糸膜が得られ
ることを見出し、本発明に到達した。Means for Solving the Problems The present inventor has conducted intensive studies to achieve the above object, and as a result, has found a hollow fiber having a two-layer structure having an extremely thin dense layer on the inner surface and a porous layer on the support layer. When the membrane has a specific water permeation performance, a low-deterioration cellulose derivative selectively permeable hollow fiber membrane excellent in water retention rate during blood treatment and retention rate of β 2 -MG sieving coefficient can be obtained. The inventors have found that the present invention has been achieved.
【0012】即ち本発明は、内径が100〜300μ
m、膜厚が30〜60μm、空孔率が60〜90%、純
水の限外濾過係数が200〜850ml/m2 ・mmH
g・Hr,β2 ―ミクログロブリンの篩係数が0.5以
上の選択透過性中空糸膜であって、該選択透過性中空糸
膜の血液の透水性保持率及びβ2 ―ミクログロブリンの
篩係数の保持率が共に80%以上であることを特徴とす
る実質的にセルロース誘導体より成る選択透過性中空糸
膜である。That is, according to the present invention, the inner diameter is 100 to 300 μm.
m, thickness: 30 to 60 μm, porosity: 60 to 90%, ultrafiltration coefficient of pure water: 200 to 850 ml / m 2 · mmH
A selectively permeable hollow fiber membrane having a g · Hr, β 2 -microglobulin sieving coefficient of 0.5 or more, wherein the selectively permeable hollow fiber membrane retains blood permeability and β 2 -microglobulin sieving. A permselective hollow fiber membrane consisting essentially of a cellulose derivative, characterized in that the coefficient retention rates are both 80% or more.
【0013】以下、本発明について更に詳細に説明す
る。本発明における中空糸膜を形成する素材は、セルロ
ース誘導体であり、特にアセチルセルロースである。Hereinafter, the present invention will be described in more detail. The material forming the hollow fiber membrane in the present invention is a cellulose derivative, particularly acetyl cellulose.
【0014】その中でも一般的に使用されるものとして
は、実質的にセルロースジアセテート、セルローストリ
アセテートからなるポリマーである。これらの中でもセ
ルローストリアセテートが特に好ましい。なお、実質的
とは、このセルロース誘導体の特性を損わない範囲で、
他の高分子量物質や添加物を含有してもよいことを意味
する。Among them, those generally used are polymers substantially consisting of cellulose diacetate and cellulose triacetate. Among these, cellulose triacetate is particularly preferred. In addition, substantially means that the properties of the cellulose derivative are not impaired.
It means that other high molecular weight substances and additives may be contained.
【0015】本発明の中空糸膜の膜壁の構造は、内面に
物質の分離透過特性を決定する極薄の緻密層を有し、そ
の外側に膜の機械特性を分担する支持層を有するもので
あり、該支持層は、対象物質の透過抵抗の殆んどない多
孔層である、2層又は多層構造が好ましい。The structure of the membrane wall of the hollow fiber membrane according to the present invention has an extremely thin dense layer for determining the separation and permeation characteristics of a substance on the inner surface, and a support layer for sharing the mechanical properties of the membrane on the outer surface. The support layer is preferably a two-layer or multilayer structure, which is a porous layer having almost no permeation resistance of the target substance.
【0016】血液濾過透析で血液透水性能の経時変化及
びβ2 ―MGの篩係数の経時変化を少なくするために
は、膜内面に緻密層を有する膜構造が必須である。この
際、緻密層の構造をより緻密にする反面、緻密層の厚さ
を1〜2μmと極薄とすることにより、透過・濾過性能
を損わないで、血液濾過透析の際の膜の目詰りによる中
空糸膜の経時的性能低下を抑制することができる。In order to reduce the time-dependent change in blood permeability and the time-dependent change in the sieving coefficient of β 2 -MG in hemodiafiltration, a membrane structure having a dense layer on the inner surface of the membrane is essential. At this time, while the structure of the dense layer is made more dense, the thickness of the dense layer is made extremely thin as 1 to 2 μm, so that the permeation / filtration performance is not impaired. It is possible to suppress the performance of the hollow fiber membrane over time due to clogging.
【0017】中空糸の膜厚は、本発明に係わるような2
層の構造のものでは、多孔層を有するため、機械的強度
の面より30μm以上が必要である。膜厚が厚くなる
程、透析器に充填できる中空糸本数が減少し透析器の膜
面積が低下するため、膜厚は30〜60μmが好まし
い。[0017] The thickness of the hollow fiber is 2 as in the present invention.
Since the layer structure has a porous layer, it needs to be 30 μm or more from the viewpoint of mechanical strength. As the film thickness increases, the number of hollow fibers that can be filled in the dialyzer decreases and the membrane area of the dialyzer decreases, so the film thickness is preferably 30 to 60 μm.
【0018】なお、中空糸膜の内径は100〜300μ
m、とりわけ150〜250μmが好ましい。The inner diameter of the hollow fiber membrane is 100 to 300 μm.
m, particularly preferably 150 to 250 μm.
【0019】本発明の中空糸膜の水透過性能(UFR)
は200〜850ml/m2 ・mmHg・Hrである。
従来の比較的均一構造の膜では、このような高レベルの
水透過性能は得られ難かった。このようなUFRをもた
せることで、一定量の除水をするためのTMP(中空糸
膜の両側にかかる差圧)を低めることができ、中空糸膜
への血中蛋白質の付着を抑えることができる。また、本
発明の中空糸膜は、内面に緻密層を有する多孔層の2層
構造であり、内面をより緻密な2μm以下の緻密層にす
ることにより血液濾過透析での血液透水性能の経時変化
及びβ2 ―MGの篩係数の経時変化を少なくすることが
可能になった。尚内面緻密層の厚さ、及び緻密度(ポラ
ス性)は、紡糸条件特にポリマー濃度、芯剤の水分率、
紡糸温度等により決めることが出来る。Water permeation performance (UFR) of the hollow fiber membrane of the present invention
Is 200 to 850 ml / m 2 · mmHg · Hr.
It was difficult to obtain such a high level of water permeation performance with a conventional film having a relatively uniform structure. By providing such a UFR, TMP (differential pressure applied to both sides of the hollow fiber membrane) for removing a certain amount of water can be reduced, and adhesion of blood protein to the hollow fiber membrane can be suppressed. it can. In addition, the hollow fiber membrane of the present invention has a two-layer structure of a porous layer having a dense layer on the inner surface. And the change with time of the sieving coefficient of β 2 -MG can be reduced. The thickness and density (porosity) of the inner dense layer are determined by spinning conditions, particularly the polymer concentration, the moisture content of the core agent,
It can be determined by the spinning temperature and the like.
【0020】本発明の中空糸膜の空孔率は60〜90%
である。空孔率が60%以下の場合は、目的とする透過
性能が得られない。90%以上では、中空糸膜の機械強
度が低下して、製造時の取扱いによるリーク等の問題が
発生する。空孔率の測定は、中空糸膜を1時間水洗した
後、中空糸表面及び中空糸管内の水を除き、重量を測定
し(重量W1 )、次に、中空糸膜を絶乾して重量を測定
し(重量W2 )、次式により求める。 空孔率=(1−W2 /W1 )×100% 絶乾とは、130℃の熱風乾燥機中で3.5時間乾燥し
た状態をいう。The porosity of the hollow fiber membrane of the present invention is 60 to 90%.
It is. If the porosity is 60% or less, the desired transmission performance cannot be obtained. If it is 90% or more, the mechanical strength of the hollow fiber membrane decreases, and problems such as leakage due to handling during production occur. The porosity was measured by rinsing the hollow fiber membrane for 1 hour, removing the water on the surface of the hollow fiber and the hollow fiber tube, measuring the weight (weight W 1 ), and then drying the hollow fiber membrane completely. The weight is measured (weight W 2 ) and determined by the following equation. Porosity = (1−W 2 / W 1 ) × 100% Absolute drying refers to a state of drying in a 130 ° C. hot air dryer for 3.5 hours.
【0021】本発明の中空糸膜のβ2 ―MGの篩係数
は、0.5以上が必要である。透析アミロイドシスの原
因物質のβ2 ―MG(分子量11,800)、関節痛、
骨痛に係わると考えられている分子量2〜4万の物質な
ど、比較的中高分子量領域の有害物質の除去の必要性か
ら、高い方が好ましい。なおβ2 ―MGの篩係数は大き
いほど好ましいが、通常は0.95以下である。The sieving coefficient of β 2 -MG of the hollow fiber membrane of the present invention must be 0.5 or more. Β 2 -MG (molecular weight 11,800), a causative substance of dialysis amyloidosis, arthralgia,
Higher is preferable from the necessity of removing a harmful substance in a relatively high molecular weight region such as a substance having a molecular weight of 20,000 to 40,000, which is considered to be related to bone pain. The larger the sieve coefficient of β 2 -MG is, the more preferable it is, but usually it is 0.95 or less.
【0022】本発明の中空糸膜の純水の限外濾過係数は
200〜850ml/m2 ・mmHg・Hrが必要であ
る。さらに該中空糸膜を用いて製作したモジュールの膜
面積1m2 当りの濾過速度10ml/分で血液濾過する
場合、本発明の透水性保持率は、80%以上が必要で、
95%以上であればなお好ましい。透水性保持率が80
%以下では、目詰りによる濾過効率の低下が大きい上
に、低分子量物質のクリアランスの低下を起こすため好
ましくない。The ultrafiltration coefficient of pure water of the hollow fiber membrane of the present invention needs to be 200 to 850 ml / m 2 · mmHg · Hr. Further, when blood filtration is performed at a filtration rate of 10 ml / min per 1 m 2 of a membrane area of a module manufactured using the hollow fiber membrane, the water permeability retention rate of the present invention needs to be 80% or more.
More preferably, it is 95% or more. 80 permeability retention
% Or less is not preferred because the filtration efficiency is greatly reduced due to clogging and the clearance of low molecular weight substances is reduced.
【0023】本発明の中空糸膜を用いて作製したモジュ
ール膜面積1m2 当りの濾過速度10ml/分とする血
液濾過を行う時、該中空糸膜のβ2 ―MGの篩係数の保
持率は80%以上が必要で、95%以上であればなお好
ましい。β2 ―MGの篩係数の保持率は80%以下の場
合は、β2 ―MGの除去効率の低下でなく、2〜4万の
中高分子量領域の有害物質の除去効率も低下するので、
好ましくない。When performing blood filtration at a filtration rate of 10 ml / min per 1 m 2 of a module membrane area prepared using the hollow fiber membrane of the present invention, the retention rate of the β 2 -MG sieving coefficient of the hollow fiber membrane is as follows. 80% or more is required, and 95% or more is more preferable. When the retention rate of the sieving coefficient of β 2 -MG is 80% or less, not only does the removal efficiency of β 2 -MG decrease, but also the removal efficiency of harmful substances in the medium-high molecular weight region of 20,000 to 40,000 decreases.
Not preferred.
【0024】なお、本発明において保持率とは、上記の
血液濾過開始後15分経過時点の血液の限外濾過係数及
びβ2 ―MGの篩係数に対する、血液濾過開始後4時間
経過時点の血液の限外濾過係数及びβ2 ―MGの篩係数
の比である。 保持率=血液濾過開始後4時間経過時点の特性/血液濾
過開始後15分経過時点の特性 なお本発明の中空糸膜の製造において、中空糸紡糸原液
に使用できる溶剤としては、N―メチルピロリドン、ジ
メチルホルムアミド、ジメチルスルホキシド、ジメチル
アミド、ジメチルアセトアミド等である。In the present invention, the retention is defined as the blood ultrafiltration coefficient and the β 2 -MG sieving coefficient at 15 minutes after the start of blood filtration, and the blood at 4 hours after the start of blood filtration. Is the ratio of the ultrafiltration coefficient and the sieving coefficient of β 2 -MG. Retention rate = Characteristics at 4 hours after the start of hemofiltration / Characteristics at 15 minutes after the start of hemofiltration In the production of the hollow fiber membrane of the present invention, N-methylpyrrolidone is used as a solvent for the hollow fiber spinning stock solution. , Dimethylformamide, dimethylsulfoxide, dimethylamide, dimethylacetamide and the like.
【0025】非溶剤としては、プロピレングリコール、
エチレングリコール、トリエチレングリコール、ポリエ
チレングリコール等の多価アルコールが使用できる。As the non-solvent, propylene glycol,
Polyhydric alcohols such as ethylene glycol, triethylene glycol, and polyethylene glycol can be used.
【0026】該中空糸の凝固浴は、上記の溶剤と非溶剤
の水溶液を用いる。また内面に緻密層を有する非対称膜
構造にするため、芯剤はより低濃度の溶剤と非溶剤の水
溶液を使用し、中外層部での相分離を促進することが必
要である。For the coagulation bath of the hollow fiber, an aqueous solution of the above-mentioned solvent and non-solvent is used. Further, in order to form an asymmetric membrane structure having a dense layer on the inner surface, it is necessary to use a lower concentration of an aqueous solution of a solvent and a non-solvent as a core agent to promote phase separation in the middle and outer layers.
【0027】紡糸原液の組成は、一般的にセルロース誘
導体10〜20重量%、溶剤55〜75重量%、非溶剤
10〜30重量%であり、好ましくはセルロース誘導体
10〜15重量%、溶剤60〜70重量%、非溶剤15
〜25重量%である。The composition of the spinning dope is generally 10 to 20% by weight of a cellulose derivative, 55 to 75% by weight of a solvent and 10 to 30% by weight of a non-solvent, preferably 10 to 15% by weight of a cellulose derivative and 60 to 60% by weight of a solvent. 70% by weight, non-solvent 15
2525% by weight.
【0028】凝固浴の組成は、溶剤/非溶剤/水の重量
比で一般的に30〜55/5〜20/30〜65好まし
くは35〜45/10〜15/40〜55である。The composition of the coagulation bath is generally from 30 to 55/5 to 20/30 to 65, preferably from 35 to 45/10 to 15/40 to 55 by weight of solvent / non-solvent / water.
【0029】芯剤の組成は、溶剤/非溶剤/水の重量比
で、5〜25/2〜15/70〜95好ましくは10〜
20/3〜10/80〜90である。The composition of the core agent is preferably 5 to 25/2 to 15/70 to 95, and more preferably 10 to 25 by weight in a solvent / non-solvent / water ratio.
20/3 to 10/80 to 90.
【0030】紡糸口金の温度は、原液組成により異なる
が30〜100℃であり、凝固浴の温度は10〜70
℃、好ましく30〜60℃である。紡糸方式としては半
乾半湿式紡糸法が好ましい。The temperature of the spinneret varies depending on the composition of the stock solution, but is 30 to 100 ° C., and the temperature of the coagulation bath is 10 to 70 ° C.
° C, preferably 30 to 60 ° C. As a spinning method, a semi-dry semi-wet spinning method is preferable.
【0031】[0031]
【作用】かかる本発明によれば、極めた高て透水性と優
れた分離特性とを有する中空糸膜が得られ、血液透析の
分野において極めて有益である。According to the present invention, a hollow fiber membrane having extremely high water permeability and excellent separation characteristics can be obtained, which is extremely useful in the field of hemodialysis.
【0032】[0032]
【実施例】以下、本発明について、実施例をあげて更に
具体的に説明するが、本発明はこれらの実施例によって
何ら限定されるものではない。EXAMPLES Hereinafter, the present invention will be described more specifically with reference to examples, but the present invention is not limited to these examples.
【0033】なお実施例及び比較例中において、評価項
目の測定は、下記の方法で行った。即ち、血液濾過透析
における中空糸膜の透水性保持率、及びβ2 ―MGの篩
係数保持率の測定は日本透析医学会学術委員会の血液浄
化器の牛血漿in vitro評価プロトコールと機能
分類(’94.11.12)による測定に基づき、下記
式で求めた。In the examples and comparative examples, the evaluation items were measured by the following methods. That is, the measurement of the permeability retention rate of the hollow fiber membrane and the retention rate of the β 2 -MG sieving coefficient in hemofiltration dialysis were carried out using the in vitro evaluation protocol of bovine plasma of a blood purifier by the Scientific Committee of the Japanese Society for Dialysis Medicine and the functional classification ( Based on the measurement according to '94 .11.12), it was determined by the following equation.
【0034】[0034]
【数1】 (Equation 1)
【0035】 UFR=限外濾過係数[ml/m2 ・mmHg・Hr] PBi=血液側入口圧力[mmHg] PBo=血液側出口圧力[mmHg] PF =濾過側浄化器内圧力[mmHg]UFR = ultrafiltration coefficient [ml / m 2 · mmHg · Hr] P Bi = blood side inlet pressure [mmHg] P Bo = blood side outlet pressure [mmHg] P F = filtration side purifier internal pressure [mmHg] ]
【0036】[0036]
【数2】 (Equation 2)
【0037】 SC:篩係数 CF :濾液側溶液濃度 CBi:血液側入口溶液濃度 CBo:血液側出口溶液濃度SC: sieving coefficient C F : concentration of the solution on the filtrate side C Bi : concentration of the solution on the blood side inlet C Bo : concentration of the solution on the blood side outlet
【0038】[実施例1〜5、比較例1〜2]セルロー
ストリアセテート13部とトリエチレングリコール20
部をジメチルスルホキシド67部に均一溶解したものを
紡糸原液とし、ジメチルスルホキシド/トリエチレング
リコール=37/13(wt/wt)の80wt%の水
溶液を芯剤として2重管ノズルより空気中(約5cm)
に吐出した後、40℃の凝固液(ジメチルスルホキシド
/トリエチレングリコール=37/13(wt/wt)
の50wt%水溶液)の中に導入し、固化させ、水洗、
グリセリン付着処理後、捲取った。得られた中空糸膜を
乾燥後束状にし、円管状の容器内に挿入充填して、両端
をポリウレタンで接着固定し、有効面積が約1.5m2
の中空糸膜透析器を作成し、血液濾過での性能評価に供
した。結果を表―1に示す。Examples 1 to 5 and Comparative Examples 1 and 2 13 parts of cellulose triacetate and 20 parts of triethylene glycol 20
Of a dimethylsulfoxide solution in 67 parts of dimethylsulfoxide is used as a spinning solution, and an 80 wt% aqueous solution of dimethylsulfoxide / triethylene glycol = 37/13 (wt / wt) is used as a core agent in the air (about 5 cm) from a double tube nozzle. )
And then coagulated at 40 ° C. (dimethyl sulfoxide / triethylene glycol = 37/13 (wt / wt)
50 wt% aqueous solution), solidified, washed with water,
After the glycerin adhesion treatment, it was wound up. The obtained hollow fiber membrane is dried and formed into a bundle, inserted and filled in a cylindrical container, and both ends are bonded and fixed with polyurethane, and the effective area is about 1.5 m 2.
Was prepared and used for performance evaluation in hemofiltration. The results are shown in Table-1.
【0039】[比較例3]セルローストリアセテート2
0部とプロピレングリコール23部とをN―メチルピロ
リドン57部に均一に溶解したものを紡糸原液とし、流
動パラフィンを芯剤として、2重管ノズルより空気中に
吐出させた後、水:プロピレングリコール:N―メチル
ピロリドン=80:8:12の重量比で混合した25℃
の凝固浴に導いて、固化させ、水洗、グリセリン付着処
理後、捲取った。得られた中空糸膜中の芯剤を抜取り、
洗浄後、得られた中空糸膜を円管状の容器内に挿入充填
して、乾燥後、両端をポリウレタンで接着固定し、有効
面積が約1.5m2 の血液透析器を製作し、血液濾過で
の性能評価に供した。結果を表―1に示す。Comparative Example 3 Cellulose Triacetate 2
0 part and 23 parts of propylene glycol are uniformly dissolved in 57 parts of N-methylpyrrolidone to obtain a spinning dope, and liquid paraffin is used as a core agent and discharged into the air from a double tube nozzle. : N-methylpyrrolidone = 25 ° C mixed at a weight ratio of 80: 8: 12
And solidified, washed with water, treated with glycerin, and wound up. Remove the core agent in the obtained hollow fiber membrane,
After washing, the obtained hollow fiber membrane is inserted and filled in a cylindrical container, and after drying, both ends are adhered and fixed with polyurethane to produce a hemodialyzer having an effective area of about 1.5 m 2. For performance evaluation. The results are shown in Table-1.
【0040】[0040]
【表1】 [Table 1]
【0041】実施例1〜3では、実施例1の中空糸膜断
面の電顕写真に示す通り、内面に約1μmの極薄緻密層
を有し、多孔層の支持層からなる2層構造の膜で、純水
の限外濾過係数が205.2〜812.4ml/m2 ・
mmHg・Hrの範囲で、血液の限外濾過係数およびβ
2 ―MGの篩係数の保持率は共に80%以上で、中空糸
膜の濾過性能の劣化は極めて少ない。In Examples 1 to 3, as shown in the electron micrograph of the cross section of the hollow fiber membrane of Example 1, a two-layer structure having an extremely thin dense layer of about 1 μm on the inner surface and a support layer of a porous layer was used. The membrane has an ultrafiltration coefficient of pure water of 205.2 to 812.4 ml / m 2.
In the range of mmHg · Hr, the ultrafiltration coefficient of blood and β
The retention rate of the 2- MG sieving coefficient is 80% or more, and the filtration performance of the hollow fiber membrane is extremely low.
【0042】実施例4〜5で、限外濾過速度を10ml
/minから20及び40ml/minに増した場合に
も、血液の限外濾過係数およびβ2 ―MGの篩係数の保
持率は共に80%以上で、中空糸膜の濾過性能の劣化は
極めて少ない。In Examples 4 and 5, the ultrafiltration rate was 10 ml.
/ Min from 20/40 ml / min, the ultrafiltration coefficient of blood and the retention rate of the sieving coefficient of β 2 -MG are both 80% or more, and the deterioration of the filtration performance of the hollow fiber membrane is extremely small. .
【0043】比較例1及び2では、純水の限外濾過係数
が200ml/m2 ・mmHg・Hr以下の場合は、血
液濾過における濾過性能の保持率が80%以下で、低下
が大きい。In Comparative Examples 1 and 2, when the ultrafiltration coefficient of pure water is 200 ml / m 2 · mmHg · Hr or less, the retention of filtration performance in blood filtration is 80% or less, and the decrease is large.
【0044】比較例3では、芯剤に流動パラフィンを使
用した従来技術の均一緻密膜構造の中空糸での血液の限
外濾過係数および、β2 ―MGの篩係数の保持率を示す
が、血液濾過における濾過係数の保持率が68.2%と
低下が大きい。Comparative Example 3 shows the ultrafiltration coefficient of blood and the retention rate of the β 2 -MG sieving coefficient of a hollow fiber having a uniform dense membrane structure according to the prior art using liquid paraffin as a core agent. The retention rate of the filtration coefficient in hemofiltration is as large as 68.2%.
【0045】[0045]
【発明の効果】本発明の中空糸膜は、血液透析に使用し
た場合に膜の目詰りによる、濾過性能の経時変化が極め
て少なく、透析患者の長期合併症と関連して透析アミロ
イドシスの原因物質のβ2 ―MGを除去するのに優れた
選択透過性中空糸膜である。本発明の膜は血液の限外濾
過係数が従来の中空糸膜より非常に高く、β2 ―MG篩
係数も高いことから、骨痛、関節痛に係わると考えられ
る分子量2〜4万の物質など比較的中高分子量領域の有
害物質の除去にも効果が期待できる。The hollow fiber membrane of the present invention, when used for hemodialysis, has very little change over time in filtration performance due to clogging of the membrane, and causes dialysis amyloidosis in connection with long-term complications of dialysis patients. It is a permselective hollow fiber membrane excellent in removing the substance β 2 -MG. Since the membrane of the present invention has an ultrafiltration coefficient of blood much higher than that of a conventional hollow fiber membrane and a high β 2 -MG sieving coefficient, it has a molecular weight of 20,000 to 40,000, which is considered to be involved in bone pain and joint pain. It can also be expected to remove harmful substances in the relatively medium-high molecular weight region.
【図1】実施例2で得られた中空糸膜断面部(緻密層と
多孔層を含む)の電子顕微鏡写真(×20,000)で
ある。FIG. 1 is an electron micrograph (× 20,000) of a cross section of a hollow fiber membrane (including a dense layer and a porous layer) obtained in Example 2.
【図2】比較例3で得られた中空糸膜層断面部の電子顕
微鏡写真(×20,000)である。FIG. 2 is an electron micrograph (× 20,000) of a cross section of a hollow fiber membrane layer obtained in Comparative Example 3.
───────────────────────────────────────────────────── フロントページの続き (56)参考文献 特開 平2−211229(JP,A) 特開 平7−148252(JP,A) 特開 平7−278948(JP,A) 特開 平8−38598(JP,A) 特開 平8−970(JP,A) 特開 平9−70525(JP,A) 特公 平3−76970(JP,B2) 特公 平8−29231(JP,B2) (58)調査した分野(Int.Cl.7,DB名) A61M 1/16 - 1/18 B01D 69/02,69/08,71/16 ──────────────────────────────────────────────────続 き Continuation of the front page (56) References JP-A-2-211229 (JP, A) JP-A-7-148252 (JP, A) JP-A-7-278948 (JP, A) JP-A 8- 38598 (JP, A) JP-A-8-970 (JP, A) JP-A-9-70525 (JP, A) JP-B3-76970 (JP, B2) JP-B 8-29231 (JP, B2) (58) Field surveyed (Int.Cl. 7 , DB name) A61M 1/16-1/18 B01D 69 / 02,69 / 08,71 / 16
Claims (3)
孔層を有する2層構造を備え、内径が100〜300μ
m、膜厚が30〜60μm、空孔率が60〜90%、純
水の限外濾過係数が200〜850ml/m2・mmH
g・Hr、β2―ミクログロブリンの篩係数が0.5以
上の選択透過性中空糸膜であって、該選択透過性中空糸
膜の血液の透水性保持率及びβ2―ミクログロブリンの
篩係数の保持率が共に80%以上であることを特徴とす
る実質的にセルローストリアセテートより成る血液透析
用の選択透過性中空糸膜。1. A two-layer structure having an extremely thin dense layer on an inner surface and a porous layer on a support layer, and having an inner diameter of 100 to 300 μm.
m, thickness: 30 to 60 μm, porosity: 60 to 90%, ultrafiltration coefficient of pure water: 200 to 850 ml / m 2 · mmH
A selectively permeable hollow fiber membrane having a g · Hr, β 2 -microglobulin sieving coefficient of 0.5 or more, wherein the selectively permeable hollow fiber membrane has a blood water permeability retention rate and a β 2 -microglobulin sieve. Hemodialysis consisting essentially of cellulose triacetate , wherein the retention rates of the coefficients are both 80% or more.
Permeable hollow fiber membranes for use .
ロブリンの篩係数が0.5以上0.95以下であること
を特徴とする請求項1記載の選択透過性中空糸膜。2. The permselective hollow fiber membrane according to claim 1, wherein the β 2 -microglobulin sieve coefficient of the permselective hollow fiber membrane is 0.5 or more and 0.95 or less.
持率及びβ2―ミクログロブリンの篩係数の保持率が共
に90%以上であることを特徴とする請求項1記載の選
択透過性中空糸膜。3. The selective permeation according to claim 1, wherein both the retention rate of blood permeability and the retention rate of β 2 -microglobulin sieving coefficient of the permselective hollow fiber membrane are 90% or more. Hollow fiber membrane.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP24397296A JP3253861B2 (en) | 1996-08-28 | 1996-08-28 | Permselective hollow fiber membrane |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP24397296A JP3253861B2 (en) | 1996-08-28 | 1996-08-28 | Permselective hollow fiber membrane |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH1066725A JPH1066725A (en) | 1998-03-10 |
| JP3253861B2 true JP3253861B2 (en) | 2002-02-04 |
Family
ID=17111796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP24397296A Expired - Lifetime JP3253861B2 (en) | 1996-08-28 | 1996-08-28 | Permselective hollow fiber membrane |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3253861B2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004305561A (en) * | 2003-04-09 | 2004-11-04 | Toyobo Co Ltd | Hollow yarn type blood purification membrane |
| WO2005025649A1 (en) * | 2003-08-22 | 2005-03-24 | Toyo Boseki Kabushiki Kaisha | Polysulfone based selective permeation hollow fiber membrane and method for production thereof |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001038154A (en) * | 1999-08-03 | 2001-02-13 | Kuraray Co Ltd | Separation membrane for plasma components |
| JP2002143298A (en) * | 2000-11-16 | 2002-05-21 | Toray Ind Inc | Blood treatment apparatus |
| JP5292762B2 (en) * | 2007-10-18 | 2013-09-18 | 東洋紡株式会社 | Blood purifier with excellent mass replacement characteristics |
| JP5299617B2 (en) * | 2008-11-21 | 2013-09-25 | 東洋紡株式会社 | Method for producing hollow fiber membrane |
| JP5440332B2 (en) * | 2010-04-02 | 2014-03-12 | 東洋紡株式会社 | Hollow fiber membrane |
-
1996
- 1996-08-28 JP JP24397296A patent/JP3253861B2/en not_active Expired - Lifetime
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004305561A (en) * | 2003-04-09 | 2004-11-04 | Toyobo Co Ltd | Hollow yarn type blood purification membrane |
| WO2005025649A1 (en) * | 2003-08-22 | 2005-03-24 | Toyo Boseki Kabushiki Kaisha | Polysulfone based selective permeation hollow fiber membrane and method for production thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH1066725A (en) | 1998-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6013182A (en) | Selectively permeable hollow fiber membrane and process for producing same | |
| WO1997034687A1 (en) | Hollow yarn membrane used for blood purification and blood purifier | |
| JP2792556B2 (en) | Blood purification module, blood purification membrane and method for producing the same | |
| US5736046A (en) | High-flux hollow-fiber membrane with enhanced transport capability and process for making same | |
| JP3253861B2 (en) | Permselective hollow fiber membrane | |
| JP2703266B2 (en) | Polysulfone hollow fiber membrane and method for producing the same | |
| JPH10263375A (en) | Selective permeable hollow fiber membrane | |
| JPH09308685A (en) | Hollow fiber membrane for blood purification and blood purifying device | |
| JP3020016B2 (en) | Hollow fiber membrane | |
| JP3295321B2 (en) | Permselective hollow fiber membrane | |
| JP2001190934A (en) | Hollow fiber membrane module with a little effluent | |
| JP3295314B2 (en) | Permselective hollow fiber membrane | |
| JP4190361B2 (en) | Hollow fiber type body fluid treatment device, hollow fiber bundle used therefor, and method for producing them | |
| JP3424810B2 (en) | High performance blood purification membrane | |
| JP3424807B2 (en) | Hollow fiber membrane | |
| JP3253867B2 (en) | Permselective hollow fiber membrane | |
| JP3205268B2 (en) | Method for producing selectively permeable hollow fiber membrane | |
| JP3995228B2 (en) | Hollow fiber membrane for blood purification | |
| JP2000107577A (en) | Production of permselective hollow fiber membranes | |
| JPH09308684A (en) | Selective separating membrane | |
| JP3253885B2 (en) | Permselective hollow fiber membrane | |
| JP3345260B2 (en) | Permselective hollow fiber membrane | |
| JP3205267B2 (en) | Method for producing selectively permeable hollow fiber membrane | |
| JP3236233B2 (en) | Method for producing selectively permeable hollow fiber membrane | |
| JP3316145B2 (en) | Permselective hollow fiber membrane and method for producing the same |